Physician profile
Charles D Russo
NPI 1588633614
$1,789.34
in general payments reported to CMS, 2019-2025
15 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $39.01 · 2021: $75.11 · 2022: $80.26 · 2023: $312 · 2024: $598 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.51 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $366.90 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $141.45 | 2019-2021 | |
| Atricure, INC. | $135.23 | 2024 | |
| Cvrx, INC. | $120.76 | 2023-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.80 | 2021-2024 | Lifevest |
| Pfizer INC. | $67.83 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $67.18 | 2023-2025 | |
| Abbott Laboratories | $63.59 | 2022-2024 | Cardiomems |
| Amgen INC. | $63.50 | 2019-2023 | Repatha |
| Boston Scientific Corporation | $60.66 | 2023-2024 | Watchman Flx |
| Heartflow, INC. | $31.73 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $25.02 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $21.17 | 2019 | |
| Amarin Pharma, INC. | $16.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.